GLUE | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

-1.26%

1 Month

-18.02%

3 Months

31.53%

6 Months

91.06%

1 Year

25.44%

2 Year

3.83%

Key data

Stock price

$7.21

P/E Ratio

0.00

DAY RANGE

$6.86 - $7.35

EPS

$0.00

52 WEEK RANGE

$3.64 - $12.40

52 WEEK CHANGE

$18.89

MARKET CAP

378.670 M

YIELD

N/A

SHARES OUTSTANDING

61.373 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

2.55

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,655,308

AVERAGE 30 VOLUME

$1,846,284

Company detail

CEO: Markus Warmuth
Region: US
Website: monterosatx.com
Employees: 90
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Monte Rosa Therapeutics, Inc. engages in the development of novel small molecule precision medicines. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers.

GLUE - Monte Rosa Therapeutics, Inc.